The death of James Van Der Beek at 48 is heartbreaking.

When someone so visible, so full of life, is taken by cancer, it hits differently. It shakes people. It raises questions. It makes us look at the system and ask: Are we doing everything we can?

Colon cancer has been rising in younger adults for years. That’s what the data says. Screening guidelines were lowered to age 45 because the trend became impossible to ignore.

But moments like this don’t just raise awareness about screening. They also reignite a deeper conversation about treatment.

Many families quietly wonder:

• Why do some cancers respond well to treatment… and others don’t?
• Why does the same chemotherapy regimen get used for decades?
• Why do some people experience remission, while others run out of options?

These are normal, human questions.

It’s important to say this clearly:

Conventional cancer treatments — surgery, chemotherapy, radiation, targeted drugs — have saved millions of lives. They are not the enemy. They are powerful tools.

But cancer is not one disease. It is complex. Adaptive. Metabolic. Individual.

That complexity is why research continues to evolve.

In recent years, more doctors and researchers have begun exploring additional approaches alongside traditional care:

• Metabolic therapies
• Repurposed medications
• Immunotherapy combinations
• Nutritional and orthomolecular support
• Lifestyle interventions
• Mitochondrial research

These conversations are not about rejecting oncology. They’re about expanding it.

Some physicians have shared clinical observations of patients stabilizing cancers using integrative approaches that include repurposed medications. Others caution that more clinical trials are needed. Both perspectives deserve space in the discussion.

The goal isn’t rebellion.

The goal is better outcomes.

When someone says, “Be open to other options,” that doesn’t mean “abandon your oncologist.” It means ask questions. It means research responsibly. It means explore what might complement standard care — especially when options feel limited.

James Van Der Beek’s passing is not a political statement about treatment. It’s a reminder that cancer is still unpredictable. It’s a reminder that we need early detection, better prevention, and continued innovation in how we approach this disease.

And it’s a reminder that hope should never be confined to one lane.

If you or someone you love is facing cancer:

• Get screened early.
• Seek expert medical guidance.
• Stay informed.
• Ask about integrative approaches.
• Advocate for yourself.

There is room for conventional medicine.

There is room for emerging science.

There is room for thoughtful exploration.

The conversation doesn’t have to be either/or.

It can be both.

Disclaimer:

This article is for educational purposes only. Journey to Wellness does not provide medical advice or recommend any specific treatment. Always consult a licensed healthcare professional before making decisions regarding cancer care.

The post When a Public Loss Sparks a Bigger Conversation About Cancer Care first appeared on Journey to Wellness.

What Is Fenbendazole?

Fenbendazole is an anti-parasitic drug, commonly administered to animals to eliminate worms and other parasites. Recently, scientists have been investigating its potential beyond veterinary medicine, particularly its effects on cancer cells.

The Study at a Glance

A study presented at the American Association for Cancer Research (AACR) Annual Meeting in 2022 examined fenbendazole’s impact on colorectal cancer cells. Researchers treated both standard colon cancer cells and patient-derived 3D tumor organoids with fenbendazole to observe its effects.

Key Findings

• Inducing Cell Death: Within 24 hours of treatment, fenbendazole initiated apoptosis—a process where cancer cells self-destruct. This effect persisted over time, suggesting a sustained impact on cancer cell viability.
• Halting Cell Growth: The drug significantly slowed down the proliferation of cancer cells by causing cell cycle arrest. This means it interrupted the normal cycle of cell growth and division, preventing the cancer cells from multiplying.
• Impact on Cell Cycle Proteins: Fenbendazole affected specific proteins that regulate the cell cycle, particularly cyclin B1 and CDK1, which are crucial for cell division. By altering these proteins, the drug effectively halted the progression of the cell cycle in cancer cells.

Why 3D Tumor Organoids?

Traditional 2D cell cultures often fail to accurately represent the complex environment of solid tumors. In this study, researchers used 3D tumor organoids—miniature, lab-grown versions of tumors derived from patient cells. These organoids provide a more realistic model for studying cancer behavior and treatment responses, enhancing the relevance of the findings.

Implications of the Research

The study suggests that fenbendazole could potentially be repurposed as an anti-cancer agent, specifically for colorectal cancer. Its ability to induce cancer cell death and halt cell proliferation positions it as a promising candidate for further research.

Caution and Next Steps

While these findings are encouraging, it’s important to note that this research is in the early stages. The study was conducted in laboratory settings using cell cultures and animal models. Before fenbendazole can be considered a safe and effective treatment for humans with colorectal cancer, extensive clinical trials are necessary to determine appropriate dosages, efficacy, and safety.

Broader Context

The exploration of fenbendazole’s anti-cancer properties is part of a larger scientific effort to repurpose existing drugs for cancer treatment. This approach can potentially expedite the availability of new therapies, as the safety profiles of these drugs are already well-understood.

About the AACR

The AACR Annual Meeting 2022 highlighted significant advancements in cancer research, including the potential repurposing of fenbendazole as a treatment for colorectal cancer. While promising, these findings are preliminary, and further research is essential to fully understand the implications for human health.

For more detailed information, you can access the full abstract here.

The post Fenbendazole, A Potential Ally Against Colorectal Cancer first appeared on Journey to Wellness.